A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen

Investigational New Drugs

Volumn 27, Issue 6, 2009, Pages 565-570

  Mina, Lida ^a   Krop, Ian ^b   Zon, Robin T ^c   Isakoff, Steven J ^d   Schneider, Charles J ^e   Yu, Menggang ^a   Johnson, Cindy ^a   Vaughn, Latrice G ^a   Wang, Yanping ^f   Hristova Kazmierski, Maria ^f   Shonukan, Oluwatoyin O ^f   Sledge, George W ^a   Miller, Kathy D ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Northern Indiana Cancer Research Consortium   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HELEN F GRAHAM CANCER CENTER   (United States)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

Enzastaurin; Metastatic breast cancer; Phase II

Indexed keywords

ANTHRACYCLINE; ENZASTAURIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C BETA; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; HISTOPATHOLOGY; HOT FLUSH; HUMAN; HYPOXIA; LOADING DRUG DOSE; LUNG HEMORRHAGE; MASTALGIA; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE BLIND PROCEDURE; SURVIVAL RATE; SURVIVAL TIME; THORAX PAIN; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; FEMALE; HUMANS; INDOLES; MIDDLE AGED; NEOPLASM METASTASIS; TAXOIDS; TREATMENT OUTCOME;

EID: 70450279096     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9220-1     Document Type: Article

References (23)

1. PG Goekjian MR Jirousek 2001 Protein kinase C inhibitors as novel anticancer drugs Expert Opin Investig Drugs 10 2117 2140 10.1517/13543784.10.12. 2117 1:CAS:528:DC%2BD38XovFKg 11772309 (Pubitemid 34000377)
2. CA O'Brian VG Vogel E Singletary, et al. 1989 Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue Cancer Res 49 3215 3217 2720675
3. PC Gordge MJ Hulme RA Clegg, et al. 1996 Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue Eur J Cancer 32 2120 2126 10.1016/S0959-8049(96)00255-9 (Pubitemid 26419463)
4. H Li IB Weinstein 2006 Protein kinase C β enhances growth and expression of cyclin D1 in human breast cancer cells Cancer Res 66 11399 11408 10.1158/0008-5472.CAN-06-2386 1:CAS:528:DC%2BD28Xht1KnsL3P 17145886 (Pubitemid 46009971)
5. G Gliki C Wheeler-Jones I Zachary 2002 Vascular endothelial growth factor induces protein kinase C (PKC)-dependent Akt/PKB activation and phosphatidylinositol 3′-kinase-mediated PKC δ phosphorylation: role of PKC in angiogenesis Cell Biol Int 26 751 759 10.1016/S1065-6995(02)90926-1 1:CAS:528:DC%2BD38XnsFaisLk%3D 12377207 (Pubitemid 35266492)
6. MM Faul JR Gillig MR Jirousek, et al. 2003 Acyclic N-(azacycloalkyl) bisindolylmaleimides: isozyme selective inhibitors of PKCβ Bioorg Med Chem Lett 13 1857 1859 10.1016/S0960-894X(03)00286-5 1:CAS:528:DC%2BD3sXjs1ers7s%3D 12749884 (Pubitemid 36577128)
7. S Ma ST Rosen 2007 Enzastaurin Curr Opin Oncol 19 590 595 10.1097/CCO.0b013e3282f10a00 1:CAS:528:DC%2BD2sXhtFSnu73M 17906457 (Pubitemid 47508866)
8. AR Hanauske O Oberschmidt H Hanauske-Abel, et al. 2007 Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in in vitro soft-agar cloning experiments Invest New Drugs 25 205 210 10.1007/s10637-007-9038-7 1:CAS:528:DC%2BD2sXltlartr8%3D 17347872 (Pubitemid 46774707)
9. BA Teicher E Alvarez K Menon, et al. 2002 Antiangiogenic effects of a protein kinase Cbeta-selective small molecule Cancer Chemother Pharmacol 49 69 77 10.1007/s00280-001-0386-2 1:CAS:528:DC%2BD3MXptFClu7Y%3D 11855754
10. KA Keyes L Mann M Sherman, et al. 2004 LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice Cancer Chemother Pharmacol 53 133 140 10.1007/s00280-003-0713-x 1:CAS:528:DC%2BD3sXhtVSjsLfP 14593497 (Pubitemid 38186992)
11. JR Graff AM McNulty KR Hanna, et al. 2005 The protein kinase Cβ-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts Cancer Res 65 7462 7469 10.1158/0008-5472. CAN-05-0071 1:CAS:528:DC%2BD2MXns1Wqsrc%3D 16103100 (Pubitemid 41161281)
12. A-S Moreau X Jia HT Ngo, et al. 2007 Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenström macroglobulinemia Blood 109 4964 4972 10.1182/blood-2006-10-054577 1:CAS:528:DC%2BD2sXmt1Onsrw%3D 17284528 (Pubitemid 46827795)
13. MA Carducci L Musib MS Kies, et al. 2006 Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer J Clin Oncol 24 4092 4099 10.1200/JCO.2005.05. 3447 1:CAS:528:DC%2BD28XhtVantb3K 16943527 (Pubitemid 46622284)
14. S Leong R Camidge G Eckhardt, et al. 2006 A phase I dose-escalation and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced cancer ASCO 24S 2048
15. MJ Robertson BS Kahl JM Vose, et al. 2007 Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma J Clin Oncol 25 1741 1746 10.1200/JCO.2006.09.3146 1:CAS:528:DC%2BD2sXlvFyktbg%3D 17389337 (Pubitemid 46797955)
16. Y Oh R Herbst H Burris, et al. 2008 Enzastaurin, an oral serine/threonine kinase inhibitor as second- or third-line therapy of non-small cell lung cancer (NSCLC) J Clin Oncol 26 7543 1141 10.1200/JCO.2007.14.3685
17. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437 (Pubitemid 30099779)
18. National Cancer Institute (2006) Common terminology criteria for adverse events, version 3.0. Available at http://ctep.cancer.gov/forms/CTCAEv3.pdf
19. R Simon 1989 Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 10 10.1016/0197-2456(89)90015-9 1:STN:280: DyaL1M7ps1SjsQ%3D%3D 2702835 (Pubitemid 19099520)
20. E Kaplan P Meier 1958 Nonparametric estimation of incomplete observations J Am Stat Assoc 53 457 481 10.2307/2281868
21. J Rademaker-Lakhai L Beerepoot N Mehra, et al. 2007 Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C β-inhibitor enzastaurin in combination with gemcitabine and cisplatin in advanced cancer Clin Cancer Res 13 4474 4481 10.1158/1078-0432.CCR-06-2912 1:CAS:528:DC%2BD2sXotlGqtLk%3D 17671132 (Pubitemid 47219716)
22. MA Cobleigh CL Vogel D Tripathy, et al. 1999 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 2639 2648 1:CAS:528:DyaK1MXmtlWrurk%3D 10561337
23. MA Cobleigh VK Langmuir GW Sledge, et al. 2003 A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer Semin Oncol 30 Suppl 16 117 124 10.1053/j.seminoncol.2003.08.013 1:CAS:528:DC%2BD3sXhtVSjtrvF 14613032